Clinical Trial Search

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: Change in Cellular Infiltrates From Day 0 to Day 28 — 2; 0; 2; 4 Participants

Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Change in Tissue Sodium — 17.1; 16.7 mmol/L — p=0.55

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants

Primary: Change in Hyaluronate Concentration — 0.29568 mg/ml

Primary: Self-reported Pain From Baseline to 1, 3, and 6 Months Post-intervention — 50.24; 47.42; 45.42; 43.57 units on a scale — p=0.791

Primary: Low Synovitis Scores — 1 Participants

Primary: Normal Limits of TUVjoint in Healthy Subjects

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01

Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale

Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141

Primary: Self-Efficacy Exercise — 6.1 units on a scale

Primary: Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6) — 1.71; 1.68; 1.69; 1.70 pg/ml — p=0.02

Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9

Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline

Primary: Change From Baseline in 24-hour Average Hand Pain Intensity, Averaged Over the 7 Days Prior to Week 6 — -1.34; -1.70 Scores on scale — p=0.442

Primary: Brief Pain Inventory - Pain Interference — -23; -22 units on a scale — p=0.90

Primary: Number and Percent of Participants With Reduction of Immunity to Collagen Type-II After APLA-12 Treatment. — 9; 4 Participants — p=0.5179

Primary: Pain Sensitivity: Pressure Pain Detection Threshold (PPT) — 252.58; 266.17 kPa